Merck + Co., Inc.

Robert G Strachan

Daniel F Veber

William J Paleveda, Jr

Frederick W Holly

Kenneth L Shepard

Marcia E Christy

Sandor L Varga

Ruth F Nutt

Ralph F Hirschmann

Frederick W Holly, Deceased

There are disclosed cyclic octapeptide analogs of the tridecapeptide, neurotensin.

Cyclic octapeptide analogs of neurotensin

There are disclosed metabolically protected linear analogs of the carboxy terminal pentapeptide fragment of the tridecapeptide, neurotensin.

Metabolically protected analogs of neurotensin

Somatostatin analogs having the structural formula: Cyclo[(X).sub.j -(A).sub.k -(B).sub.1 -Phe-Phe-(D- or L-)Trp-Lys-Thr-Phe-Thr-(C).sub.m ] Wherein

Somatostatin analogs

Somatostatin analogs having the structural formula: ##STR1## are prepared by controlled stepwise procedures starting with individual amino acid components. These peptides have the property of lowering blood glucose, inhibiting gastric secretion, inhibiting growth hormone release and inhibiting glucagon release in humans and animals.

Somatostatin analog, hereinafter designated des(Ala.sup.1 -Gly.sup.2)desaminocys.sup.3 -somatostatin, having the structure: ##STR1## is prepared by controlled stepwise procedures starting with individual amino acid components. This peptide has the property of lowering blood glucose, inhibiting gastric secretion and inhibiting growth hormone release in humans and animals.

Process for preparing somatostatin analog

This invention is directed to the chemical process for the preparation of the polypeptide, pyroglutamyl-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn and to intermediates in said process. The polypeptide prepared by the present process is useful in the treatment of autoimmune diseases such as Lupus like pathology and specifically for the treatment of Lupus Erythematosus in man. This polypeptide is also useful for selectively stimulating T-cell activity in aging subjects.

Growing community of inventors

Warrington, PA, United States of America

Robert G Strachan